Not medical advice. Talk to your provider before using any peptide.
Full disclaimerTirzepatide vs Retatrutide
Peptide Schedule Research TeamReviewed Apr 202628 Citations
Side-by-side comparison of dosage, benefits, and side effects.
20.2% body weight gone at 72 weeks, and that was the average, not the ceiling. Tirzepatide (LY3298176, CAS 2023788-19-2) is a 39-amino acid acylated lipopeptide sold as Zepbound for obesity and Mounjaro for type 2 diabetes. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. The dual receptor mechanism separates tirzepatide from single-target GLP-1 drugs like semaglutide. GIP receptor activation improves fat metabolism and may reduce the nausea burden that limits GLP-1-only treatment. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and boosts insulin secretion. Those two pathways working together produce weight loss and glycemic control that neither achieves alone. SURMOUNT-1 (PMID 35658024, n=2,539) showed dose-dependent results at 72 weeks: 15.0% weight loss at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg. SURMOUNT-5 (PMID 40353578, n=751) ran a direct comparison; tirzepatide reached 20.2% versus semaglutide's 13.7%. Roughly one in five tirzepatide patients lost 30% or more of their body weight. The r/Zepbound community (180,000+ members) confirms what the trials found. Appetite suppression starts within days. Most users stabilize at 7.5 to 12.5 mg rather than pushing to the maximum 15 mg dose. Cost and insurance coverage remain the biggest barriers. Weight regain after stopping is well-documented; about two-thirds of lost weight returns within a year of discontinuation.
View full guide →28.7% mean body weight gone in 68 weeks. That Phase 3 number from TRIUMPH-4 (n=445, December 2025) set a new ceiling for obesity pharmacotherapy. No other drug, approved or investigational, has matched it. The retatrutide peptide (LY3437943, CAS 2381089-83-2) is a 44-amino-acid synthetic lipopeptide developed by Eli Lilly. Known in community forums as reta peptide or Triple G, it activates GLP-1, GIP, and glucagon receptors simultaneously in a single molecule. The GLP-1 component suppresses appetite and slows gastric emptying. GIP improves insulin response and buffers GLP-1 tolerability. Glucagon raises resting energy expenditure and burns liver fat directly. That third receptor is the differentiator; dual agonists like tirzepatide lack it entirely. Clinicians and researchers tracking the obesity pharmacotherapy space have been watching retatrutide since the Phase 2 readout (Jastreboff et al., NEJM 2023, PMID 37366315), where 338 adults lost up to 24.2% body weight at 48 weeks on the 12 mg dose. A separate Phase 2a MASLD trial (Nature Medicine 2024, PMID 38858523) showed 82.4% relative liver fat reduction in 98 participants at 24 weeks. Seven more Phase 3 TRIUMPH trials are still reading out. Community users who plateaued on semaglutide or tirzepatide have driven early adoption through compounding pharmacies. The enthusiasm is high; so are the GI side effects during dose escalation. NDA submission is expected in late 2026 or early 2027. Until then, retatrutide carries no FDA approval and no insurance coverage.
View full guide →At a Glance
| Attribute |  Tirzepatide |  Retatrutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Safety Grade | A | B |
| Half-Life | ~5 days | ~6 days |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 5mg, 10mg, 15mg | 5mg, 10mg, 15mg |
| Beginner Dose | 2500mcg Weekly | 1000mcg Weekly |
| Moderate Dose | 5000mcg Weekly | 4000mcg Weekly |
| Aggressive Dose | 10000mcg Weekly | 8000mcg Weekly |
| Dosing Source | FDA Label | Clinical Trial |
| Side Effects | Tirzepatide carries a black box warning for thyroid C-cell tumors. In rodent studies, it caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this translates to humans is unknown, and no confirmed human cases have been attributed to tirzepatide. The drug is contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Gastrointestinal side effects are the most common reason people struggle with tirzepatide. In the SURMOUNT and SURPASS trials, nausea affected 17 to 25% of patients (dose-dependent, worst during dose escalation). Diarrhea occurred in 13 to 17%. Vomiting hit 8 to 10%. Constipation affected 7 to 11%. Most of these effects are mild-to-moderate and improve with slow dose titration; the community-preferred 6 to 8 week steps between dose increases reduce GI burden compared to the FDA label's 4-week minimum. Decreased appetite (9 to 11%) is technically a side effect, though most users consider it the primary benefit. Sulfur burps are a community-reported nuisance during escalation phases that clinical trials don't track well. Hair thinning (telogen effluvium) affects roughly 4 to 5% of users versus about 1% on placebo. This isn't a direct drug effect. Rapid weight loss and caloric restriction trigger a hair growth cycle shift that typically starts 2 to 3 months in and resolves on its own by month 9 to 12. Injection-site reactions occur in 4 to 7% of patients. Rotating injection sites between the abdomen, thigh, and upper arm helps. Let the vial reach room temperature for 15 to 20 minutes before injecting. Pancreatitis is rare but serious. Severe, persistent abdominal pain warrants immediate medical evaluation. Serum lipase testing should happen only when pancreatitis is clinically suspected; routine screening isn't indicated. Gallbladder disease and hypersensitivity reactions are uncommon but documented in clinical trials. Stop tirzepatide and seek medical care if you develop signs of anaphylaxis, severe abdominal pain, or jaundice. Muscle loss is a legitimate concern. Approximately 25% of weight lost on tirzepatide is lean mass (SURMOUNT-1 body composition data). Resistance training 3 to 4 times per week and protein intake of at least 1.2 g/kg body weight per day are the primary countermeasures. Pregnancy and breastfeeding: tirzepatide is contraindicated. Stop treatment at least 2 months before planned conception due to the 5-day half-life and limited reproductive safety data. | Gastrointestinal events during dose escalation are the defining tolerability challenge with retatrutide, and they hit harder than comparable GLP-1 agents at equivalent titration speeds. In TRIUMPH-4 Phase 3 data (PMID 40291085), nausea occurred in 38 to 43% of participants. Diarrhea affected 33 to 35%. Constipation hit 22 to 25%. Vomiting was reported in 21%. These rates are dose-dependent and front-loaded, meaning they peak during the weeks immediately after each dose increase. Most GI events resolve within 1 to 2 weeks at a stable dose. Slow titration from 1 mg with 4-week steps between escalations reduces severity substantially. Raised resting heart rate is the second signal that deserves attention. Phase 2 trials (PMID 37366315) documented a dose-dependent increase in resting HR tied to glucagon receptor activation. Community users at 8 mg and above have reported palpitations and sustained HR above 90 bpm. Phase 3 data suggests this effect is manageable with proper monitoring, but anyone with a cardiac history should track heart rate weekly during titration. Do not escalate if resting HR stays above 100 bpm. Post-injection fatigue, sometimes called "wipeout day," shows up consistently in community reports at doses of 8 mg or higher. Users describe pronounced fatigue lasting 12 to 24 hours after injection, particularly during the first 2 to 4 weeks at a new dose level. Scheduling the injection on a low-demand day helps. The GLP-1 class carries an unresolved rodent thyroid C-cell tumor signal. No confirmed human thyroid cancer risk has been established for any GLP-1 agonist, but retatrutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Pancreatitis is a known class risk. Severe persistent abdominal pain radiating to the back warrants immediate medical attention and discontinuation. Pregnancy is an absolute contraindication. No reproductive toxicity data exist for retatrutide. Discontinue well before any planned pregnancy. Product quality adds a layer of risk specific to investigational peptides. Retatrutide is not FDA approved; compounded versions lack standardized formulation. Request a Certificate of Analysis with HPLC purity data for every batch. Grey-market research chemicals carry contamination and identity risks that cannot be verified. |
Key Differences
- Tirzepatide targets GLP-1 + GIP (dual agonist); Retatrutide targets GLP-1 + GIP + glucagon (triple agonist).
- Retatrutide's additional glucagon receptor activity may increase energy expenditure and improve liver fat.
- Tirzepatide is FDA-approved; Retatrutide is investigational.
- Both show superior weight loss compared to single GLP-1 agonists.
When to Choose Tirzepatide
- You want an FDA-approved dual agonist with strong clinical data
- You prefer a well-established dosing and titration protocol
- Your weight loss goals are achievable with dual agonist therapy
- You want a balance of efficacy and safety profile
When to Choose Retatrutide
- You want maximum weight loss potential (triple mechanism)
- Liver fat reduction is a key goal
- You haven't achieved target results with dual agonist therapy
- You're comfortable with investigational-stage peptides
Can You Stack Tirzepatide + Retatrutide?
Do not stack: Retatrutide already covers both GLP-1 and GIP pathways that Tirzepatide targets.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.